sur AMOEBA (EPA:ALMIB)
Amoéba confirms its strategic pivot in the first half of 2024
Amoéba, a greentech company specializing in microbiological solutions, has announced results for the first half of 2024, marked by a strategic turning point. The company now aims to become an industrial and commercial company by 2025.
Two product lines were prioritized: biocontrol, awaiting approval by the US EPA and EFSA, and cosmetic products, which have shown promising results in clinical trials. Operating costs were reduced, improving operating income by more than €1 million.
Financially, the company benefits from the support of Nice & Green, ensuring financial visibility until June 30, 2025. The simple bond loan amounts to €8,074,000.
R. E.
Copyright © 2024 FinanzWire, tous droits de reproduction et de représentation réservés.
Clause de non responsabilité : bien que puisées aux meilleures sources, les informations et analyses diffusées par FinanzWire sont fournies à titre indicatif et ne constituent en aucune manière une incitation à prendre position sur les marchés financiers.
Cliquez ici pour consulter le communiqué de presse ayant servi de base à la rédaction de cette brève
Voir toutes les actualités de AMOEBA